61,470 Shares in 10x Genomics $TXG Purchased by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. bought a new stake in shares of 10x Genomics (NASDAQ:TXG) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 61,470 shares of the company’s stock, valued at approximately $712,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in 10x Genomics by 235.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock worth $62,016,000 after buying an additional 4,987,195 shares during the period. Millennium Management LLC boosted its stake in 10x Genomics by 434.5% during the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock valued at $46,946,000 after purchasing an additional 4,371,327 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of 10x Genomics by 3,619.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock valued at $10,185,000 after purchasing an additional 1,135,356 shares during the period. Iron Triangle Partners LP bought a new stake in 10x Genomics during the 1st quarter valued at $8,730,000. Finally, ARK Investment Management LLC increased its holdings in shares of 10x Genomics by 7.5% during the first quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company’s stock valued at $112,143,000 after purchasing an additional 901,656 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the company a “hold” rating in a research note on Friday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, September 27th. Barclays reiterated an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a report on Monday, August 11th. Finally, Wall Street Zen lowered 10x Genomics from a “buy” rating to a “hold” rating in a report on Saturday, September 13th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $13.65.

10x Genomics Price Performance

Shares of TXG opened at $12.31 on Friday. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $20.92. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -17.59 and a beta of 2.05. The business’s 50-day moving average is $13.20 and its 200-day moving average is $10.98.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. Equities research analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Adam Taich sold 22,315 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer owned 309,273 shares of the company’s stock, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,149 shares of company stock worth $539,865 in the last three months. 9.39% of the stock is owned by insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.